cardiovascular
Dyslipidemia and GLP-1 Medications
Abnormal cholesterol and triglycerides often accompany obesity. GLP-1 medications significantly improve lipid profiles beyond what statins alone achieve.
20-30%
Triglyceride reduction
5-10 mg/dL
HDL increase
15-25%
ApoB reduction
Lipid Improvements
GLP-1 medications improve lipid profiles through weight loss and metabolic effects. Triglycerides typically drop 20-30%. HDL cholesterol increases 5-10 mg/dL. LDL particle size improves (less atherogenic). ApoB and non-HDL cholesterol decrease significantly. These improvements reduce cardiovascular risk independent of weight loss effects. Combined with statins, GLP-1s provide comprehensive lipid management.
Treatment Approach
Baseline lipid panel before starting GLP-1s. Repeat testing at 3-6 months. Continue statins if prescribed—synergistic benefits with GLP-1s. Some patients can reduce statin doses after significant weight loss. SeraVia formulations support cardiovascular health.
Medications commonly used
Find providers who understand dyslipidemia
Compare GLP-1 providers by clinical oversight, medication options, pricing, and local availability.
Related conditions